For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results